Thermo Fisher Scientific unveils Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at 2026 ASMS Conference, expanding AI-enabled proteomics capabilities.

Thermo Fisher Scientific recently unveiled the Thermo Scientific Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at the 2026 American Society for Mass Spectrometry Conference, alongside expanded AI-enabled proteomics capabilities from its Olink platform and recent software acquisitions.

The new Orbitrap platforms improve detection of low-abundance molecules and offer higher-throughput small-molecule analysis, designed to provide more complete, regulatory-ready data for complex therapies such as GLP-1 drugs, oligonucleotides and antibody-drug conjugates.

Thermo Fisher's narrative projects $54.1 billion revenue and $9.5 billion earnings by 2029, requiring 6.2% yearly revenue growth and a $2.7 billion earnings increase from $6.8 billion today.